Naloxone Adapt Pharma (Naloxone)

Naloxone competitively binds to mu, kappa and delta opioid receptors without activating them. By displacing opioid molecules from these receptors, it stops their depressant effects on the respiratory and central nervous systems, allowing breathing and alertness to return quickly.

The dose of Naloxone Adapt Pharma is determined by the prescribing clinician based on the severity of the overdose, patient age, weight, and response to initial treatment. Healthcare professionals follow local protocols to decide the appropriate amount and frequency.

Safety data for naloxone in pregnancy and lactation are limited. Because naloxone has a short half‑life and minimal systemic absorption when given intranasally, it is generally considered low risk, but clinicians should weigh potential benefits against unknown risks and monitor both mother and infant closely.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Naloxone is the most widely used opioid antagonist for emergency reversal. Compared with alternatives such as nalmefene, naloxone has a faster onset of action when administered intranasally, making it preferred for rapid community and pre‑hospital use. Both agents share similar safety profiles.

Naloxone Adapt Pharma should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight and extreme temperatures to maintain potency and ensure reliable performance when needed.

The product is administered as a single intranasal spray into one nostril. The device delivers a measured dose, and the patient should be placed in a supine or semi‑recumbent position while breathing is monitored. If necessary, additional doses may be given according to clinical guidelines.

The most serious risks include severe hypertension, cardiac arrhythmias, pulmonary edema, anaphylaxis, and precipitated acute opioid withdrawal, which can be life‑threatening in opioid‑dependent individuals. Immediate medical supervision is required after administration to manage these potential complications.

Naloxone should not be used in individuals with a known hypersensitivity to naloxone or any of the formulation components. It is also contraindicated in patients who have not experienced an opioid overdose, as its antagonistic action can induce unnecessary withdrawal symptoms.